Chutes and Ladders

Latest Headlines

Latest Headlines

Parnell shakes up management team, woos investors, as shares stagnate

In the midst of an ongoing campaign to boost its profile in the increasingly crowded animal health space, Parnell Pharmaceutical Holdings named two new top executives and one board member to its growing team on Tuesday evening. The Kansas company appointed veterinarian Edward Robb as chief scientific officer and Andy Ferrigno as vice president of global sales. Thomas E. Duley of life science consultancy King & Spalding was named to the company's board of directors.

Merck Vaccines president Gerberding leaving post for EVP role

Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.

Ex-Pfizer SVP named CEO of BioClinica

BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer, where he worked as senior vice president and worldwide head of development operations.

Venter makes new hires at Synthetic Genomics and Human Longevity

J. Craig Venter has made new hires at two of his companies.

UPDATED: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door

There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.

GE promotes biz dev exec to head healthcare

GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.

Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis

Paul Herendeen has been appointed as the new executive vice president and chief financial officer to Zoetis, the animal health industry leader. Reporting to CEO Juan Ramón Alaix, he will oversee the company's finance and IT segments.

Exosome Diagnostics replaces CEO and relocates as it preps for commercialization

Exosome Diagnostics will advance its prostate cancer urine test to market with a new CEO and a change in locale to one of the biggest biotech clusters in the world.

Philips Healthcare chief DiSanzo out in management shakeup

The chief of Philips Healthcare, Deborah DiSanzo, has left the company ahead of what is expected to be disappointing Q2 earnings. The unit will now report directly to CEO Frans van Houten, The Wall Street Journal reported.

Proxy firm backs half of Icahn's Forest nominees

At least one third party agrees with Carl Icahn about Forest Laboratories. Institutional Shareholder Services, a proxy advisory firm, has backed two of Icahn's four nominees to the Forest board.